Companies present 5,000 doses to Illinois
Governor’s Task Force and McHenry County Coalition to combat
epidemic
AptarGroup, a leading global provider of innovative drug
delivery devices and consumer dispensing systems, and Adapt Pharma,
a pharmaceutical company solely focused on expanding affordable
access to NARCAN® (naloxone) Nasal Spray, today announced a joint
donation of 4,000 doses of NARCAN® to Illinois Governor Bruce
Rauner’s Opioid Overdose Prevention and Intervention Task Force,
with another 1,000 doses scheduled to go to the McHenry County
Substance Abuse Coalition Friday.
Recognizing an unmet need in the treatment landscape, Aptar and
Adapt collaborated on the development of a nasal spray system for
NARCAN® that delivers a concentrated 4 mg dose of naloxone without
any required assembly or specialized medical training.
“We are proud of our innovative drug delivery and dispensing
solutions that improve the lives of millions of people around the
world daily. It’s especially meaningful when we are able to
contribute to saving lives. We are pleased to partner with Adapt
Pharma, Governor Rauner’s Task Force and the McHenry County
Substance Abuse Coalition to help address the opioid epidemic in
our own backyard,” said Stephan Tanda, CEO of Aptar. “Raising
awareness of the crisis and making these potentially life-saving
doses more accessible to those who most need it will have a lasting
impact on our community.”
Nearly 1,950 people died of opioid overdoses in Illinois in
2016, an 82 percent increase in just three years. Synthetic
opioids, such as fentanyl and its analogues, are disproportionately
contributing to the rise in both fatal and nonfatal overdoses in
the state, with a tenfold increase from 2013 to 2016.
With headquarters in Crystal Lake, Ill., Aptar recognized the
need in Illinois – and its home county of McHenry – for increased
access to NARCAN®. Today’s donation of 4,000 doses was received by
the Illinois Department of Public Health on behalf of the Illinois
Department of Corrections and Illinois State Police, as well as by
Chicago Recovery Alliance. The McHenry County Substance Abuse
Coalition will accept the donation of 1,000 doses on Friday.
“This product is a life-saver,” Governor Rauner said as the
presentation was made at Chicago Recovery Alliance’s Taylor Street
offices in Garfield Park this afternoon. “We will continue to fight
the root causes of this epidemic, but meanwhile, this generous
donation is most welcome and appreciated.”
“Every day, hundreds of lives are forever changed by the opioid
epidemic. NARCAN® Nasal Spray is an effective emergency treatment
that can reverse the effects of an opioid overdose when an adequate
dose is administered in time,” said Seamus Mulligan, chairman and
CEO at Adapt Pharma. “We are proud to work with Aptar and the State
of Illinois to ensure this critical intervention tool is more
readily available and in the hands of those most likely to witness
an overdose.”
The NARCAN® Nasal Spray donation will largely impact the
Illinois State Police in the line of action and benefit the
Illinois criminal justice system, giving parole agents a tool to
help save lives in the field. Additional doses will support Chicago
Recovery Alliance’s mission of harm reduction, as well as education
and distribution programs in McHenry County.
"Lives in our community are impacted on a daily basis, and we
are excited that Aptar recognizes the epidemic in their home
community," said Jason Sterwerf, chairman of the McHenry County
Substance Abuse Coalition. “The McHenry County Substance Abuse
Coalition is honored that Aptar is making a commitment to continue
to make this intervention tool available for our community partners
who confront this epidemic every day.”
The need for expanded awareness, education and access to
naloxone is more apparent than ever. NARCAN® Nasal Spray is not a
substitute for emergency medical care, and repeat applications may
be necessary. Seek emergency medical assistance immediately after
initial use, keeping the patient under continued surveillance.
About AptarGroup
AptarGroup, Inc. (NYSE: ATR) is a leading global supplier of a
broad range of innovative drug delivery devices and dispensing and
sealing solutions for the pharmaceutical, beauty, personal care,
home care, food and beverage markets. Aptar is headquartered in
Crystal Lake, Illinois, with manufacturing facilities in North
America, Europe, Asia and South America. For more information,
visit www.aptar.com.
About Adapt Pharma
Adapt Pharma is a privately-held pharmaceutical company solely
focused on expanding access to NARCAN Nasal Spray. Adapt Pharma’s
company headquarters is in Dublin, Ireland and its U.S.
headquarters are in Radnor, Pennsylvania. For more information,
please visit www.adaptpharma.com.
ABOUT NARCAN® (naloxone HCl) Nasal
Spray
NARCAN® Nasal Spray is indicated for the emergency treatment of
known or suspected opioid overdose, as manifested by respiratory
and/or central nervous system depression. NARCAN® Nasal Spray is
intended for immediate administration as emergency therapy in
settings where opioids may be present.
NARCAN® Nasal Spray is not a substitute for emergency medical
care.
Always seek emergency medical assistance in the event of a
suspected, potentially life-threatening opioid emergency after
administration of the first dose of NARCAN® Nasal Spray.
If the desired response is not obtained after 2 or 3 minutes,
administer an additional dose of NARCAN® Nasal Spray in an
alternate nostril using a new NARCAN® Nasal Spray. If the patient
responds to NARCAN® Nasal Spray and relapses back into respiratory
depression before emergency assistance arrives, administer an
additional dose and continue surveillance of the patient. If there
is still no response and additional doses are available, administer
additional doses of NARCAN® Nasal Spray every 2 to 3 minutes using
a new NARCAN® Nasal Spray in alternate nostrils with each dose
until emergency medical assistance arrives. Additional supportive
and/or resuscitative measures may be helpful while awaiting
emergency medical assistance.
See full Prescribing Information, Patient Information, and
Instructions for Use of this product, available
here: http://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180208006205/en/
Matthew DellaMariaSenior Vice President, Investor Relations and
CommunicationsAptarGroupmatt.dellamaria@aptar.com815-479-5530orThom
DuddyExecutive Director, CommunicationsAdapt
Pharmathomas.duddy@adaptpharma.com484-431-8223
AptarGroup (NYSE:ATR)
Historical Stock Chart
From Aug 2024 to Sep 2024
AptarGroup (NYSE:ATR)
Historical Stock Chart
From Sep 2023 to Sep 2024